Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Therapeutic Drug Monitoring
53%
Tuberculosis
47%
Multi-Drug-Resistant Tuberculosis
35%
Neoplasm
31%
Inflammatory Bowel Disease
25%
Voriconazole
23%
Biodistribution
23%
Tablet
23%
Polyethylene Terephthalate
21%
Linezolid
16%
Zirconium 89
16%
Infliximab
16%
Normal Human
16%
Adverse Event
15%
Fluconazole
15%
Monoclonal Antibody
15%
Bioavailability
15%
Indium 111
13%
Gamma Urogastrone
12%
Extensively Drug-Resistant Tuberculosis
11%
Tacrolimus
11%
Antiinfective Agent
10%
Inflammation
10%
Bevacizumab
10%
Clinical Trial
10%
Dosage Forms
10%
Pharmacokinetic Modeling
9%
Levofloxacin
9%
Darunavir
9%
Everolimus
9%
Vasculotropin A
9%
HIV
9%
Trastuzumab
8%
Ertapenem
8%
Pharmacodynamics
8%
Mycobacterium Tuberculosis
8%
Ethambutol
8%
Tracer
8%
Clozapine
8%
Anidulafungin
8%
Budesonide
8%
Acetylsalicylic Acid
8%
Hospital Pharmacy
8%
Trough Level
8%
Tuberculostatic Agent
7%
Malignant Neoplasm
7%
Invasive Candidiasis
7%
Biological Marker
7%
Urea C 13
7%
Keyphrases
Therapeutic Drug Monitoring
50%
Pharmacokinetics
37%
Multidrug-resistant Tuberculosis (MDR-TB)
32%
Mycobacterium Tuberculosis (M. tb)
27%
Population Pharmacokinetics (PopPK)
25%
Limited Samples
22%
Critically Ill Patients
21%
Inflammatory Bowel Disease
17%
Tumor Uptake
16%
Voriconazole
15%
Tuberculosis Patients
14%
Tuberculosis Treatment
14%
Biodistribution
13%
Linezolid
13%
ColoPulse
13%
Fluconazole
13%
Area under the Concentration-time Curve
12%
Medication Errors
12%
Hospitalized Patients
12%
Preventable Adverse Events
11%
Zirconium-89 (89Zr)
11%
Tumor
11%
Infliximab
11%
Levofloxacin
11%
Monoclonal Antibody
10%
Positron Emission Tomography/computed Tomography (PET/CT)
10%
Adverse Events
10%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
10%
Clinical Practice
9%
Extensively Drug-resistant Tuberculosis
9%
Invasive Candidiasis
9%
Zr-89
9%
Darunavir
9%
Once-daily
9%
Voriconazole Concentration
8%
Plasma Concentration
8%
Healthy Volunteers
8%
Moxifloxacin
8%
First-line Anti-tuberculosis Drugs
8%
Human Serum
8%
Amikacin
8%
Kanamycin
8%
Anidulafungin
8%
Vascular Endothelial Growth Factor
8%
Pediatric Liver Transplantation
8%
Cobicistat
7%
Drug Exposure
7%
Posaconazole
7%
MOC31
7%
TB Patients
6%